ELEVAR THERAPEUTICS
Live / Applied — Third extension granted (statement of use) (as of 23 Feb 2026)
What this means for you
Not registered yet, but its 11 Jun 2024 filing date beats anything filed after it. If it registers, the owner can stop confusingly similar uses in the classes it covers.
Record
- Serial number
- 98594659
- Mark type
- Design + words
- Filed
- 11 Jun 2024
- Published for opposition
- 17 Sept 2024
- Attorney of record
- Cynthia Johnson Walden
Goods and services
- Class 005 — Pharmaceuticals: Novel cancer therapies, namely, pharmaceutical preparations and substances for the treatment of cancer
Owner
- Elevar Therapeutics, Inc., Fort Lee, NJ, US
- Elevar Therapeutics, Inc., Salt Lake City, UT, US
Prosecution history
- 24 Feb 2026 — NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
- 23 Feb 2026 — SOU EXTENSION 3 GRANTED
- 23 Feb 2026 — SOU EXTENSION 3 FILED
- 23 Feb 2026 — SOU TEAS EXTENSION RECEIVED
- 31 Oct 2025 — NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
- 31 Oct 2025 — SOU EXTENSION 2 GRANTED
- 31 Oct 2025 — SOU EXTENSION 2 FILED
- 31 Oct 2025 — SOU TEAS EXTENSION RECEIVED
- 13 May 2025 — NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
- 13 May 2025 — SOU EXTENSION 1 GRANTED
- 12 May 2025 — SOU EXTENSION 1 FILED
- 12 May 2025 — SOU TEAS EXTENSION RECEIVED
- 12 Nov 2024 — NOA E-MAILED - SOU REQUIRED FROM APPLICANT
- 17 Sept 2024 — OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED
- 17 Sept 2024 — PUBLISHED FOR OPPOSITION